login visible
Production / Research / Quality Control
Senior Engineer
1 year or more
高温补贴 绩效奖金 交通补贴 定期体检 Five insurance and one gold high-temperature subsidy performance bonus, transportation subsidy, regular medical examination

company profiles

Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales. It is a well-known domestic R & D and production base for liver health drugs. It is a national key high-tech enterprise and a national torch plan. Backbone enterprises, ranked 16th in the Top 100 Chinese Pharmaceutical Industry Enterprises in 2016 (selected and released by China Pharmaceutical Industry Information Center).
Zhengda Tianqing always regards scientific and technological innovation as an important strategy for enterprise development, and is one of the pharmaceutical companies with a large investment in innovative drug research in China. Zhengda Tianqing regards the research institute as the innovation carrier, and has established high-level R & D platforms such as "Jiangsu New Liver Disease Engineering and Technology Research Center", "Postdoctoral Research Station", and "Nationally Recognized Enterprise Technology Center", and has continuously enhanced its independent innovation capabilities. With the development of enterprises and the enhancement of R & D capabilities, Zhengda Tianqing has invested more than 1 billion yuan in R & D expenses and will gradually align with multinational companies. At present, the institute has more than 180 research projects, including more than 30 new drugs and more than 20 biological drugs.
Zhengda Tianqing has three production bases in Lianyungang, covering a total area of more than 800 acres, including a hatching base covering an area of 160 acres, an API base covering over 200 acres, and a preparation base covering 480 acres. Zhengda Tianqing Preparation Base obtained the country's first new GMP certificate. The solid preparation workshop passed the European Union certification and the EU-approved GMP certificate issued by the German Drug Administration. The obtaining of these certificates indicates that the quality and management level of pharmaceutical production of enterprises are at the forefront of the national pharmaceutical industry. At present, Chia Tai Tianqing is preparing for the four major fist products to enter the international market. In the future, these drugs will become a new weapon for Chia Tai Tianqing to crack the international market.

The field of treatment of Zhengda Tianqing products involves liver disease, tumor, respiratory, infection, digestion and other diseases. 16 products with annual sales of over 100 million yuan have formed a "product group of 100 million yuan", of which products with annual sales of over 2 billion yuan 2 These are the national first-class new medicine magnesium isoglycyrrhizinate injection (Tianqing Ganmei) and the first domestic marketed entecavir dispersible tablet (Runzhong). In addition to the field of strong liver disease, a unique product line has also been formed in the field of anti-tumor. The blood tumor products decitabine, imatinib, and dasatinib are the first in the country; capecitabine, a solid tumor product, was approved for marketing. Anlotinib, the original and innovative drug in the Chinese tumor field that has attracted much attention, is officially on the market and is expected to become the standard drug for third-line treatment of patients with advanced non-small cell lung cancer. Respiratory, antibiotic, endocrine and other fields will also be the focus of the company's future development.
In the future development, Zhengda Tianqing Pharmaceutical will continue to strengthen the building of core competitiveness, establish a sound scientific and efficient research and development system, so that the company's research and development level is always in line with the international frontier. Develop the company into a large-scale pharmaceutical group with the scientific research strength among the top five pharmaceutical companies in the country and the top ten in the country with comprehensive strength; and launch an internationalization strategy to build the company into a scientific and technological, pharmaceutical-based international company.

Lianyungang City Address: No. 369 Yuzhou South Road, Lianyungang City, Nanjing Address: Building 9, District 699-8, Xuanwu Avenue, Xuanwu District, Nanjing (Xuzhuang Software Park R & D Zone 1)

[Expand Full Text] [Contract Full Text]
Resume delivery successful!
Cannot be re-delivered within 7 days!
The resume has been delivered!
Your resume is less than 50% complete and cannot be delivered!
Please select a position to submit!
Hunter QR code